Posts

Rare Disease Sales Projected to Exceed $400B by 2032 Despite Challenges, Driven by Small Molecule Resurgence

on

FDA Accelerates Rare Disease Drug Approvals with New Frameworks and Record 2025 Approvals

on

US Spending Bill Tweaks Orphan Drug Exclusion to Broaden Protections and Ease FDA Burden

on

Spotlight On: AI in Genomics and Multimodal Data Analysis Loosens Orphan Drug R&D Bottlenecks

on

Orphan Drug Trends: A Data-Driven Analysis

on

Spotlight On: Five Key FDA Approvals of 2025

on

Unlocking Japan's Potential in Rare Disease Drug Development: Recent Progress and Challenges (2025)

on

FDA Grants Dupixent (Dupilumab) Eighth Approval: Now Cleared for Bullous Pemphigoid

on

Regeneron Leads $66M Series B for Actio Biosciences’ Rare Disease Therapeutics

on

Senate Drops Orphan Cures Act from Trump's Tax Bill, Dealing Setback to Biopharma

on